Related Experiment Video

Updated: Apr 19, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.2K

Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma

Omar Abdel-Rahman1

  • 1Clinical oncology department, Faculty of medicine, Ain Shams University, Cairo, Egypt.

Critical Reviews in Oncology/Hematology
|January 7, 2015
PubMed

Insights

Thyroid cancer incidence is rising globally. This review focuses on vascular endothelial growth factor (VEGF) targeted therapies for advanced, iodine-refractory differentiated thyroid cancer (DTC).

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Thyroid cancer is the most common endocrine malignancy, with increasing global incidence.
  • Iodine-refractory differentiated thyroid cancer (DTC) presents challenges in treatment and survival.
  • Vascular Endothelial Growth Factor (VEGF) expression correlates with aggressive DTC phenotypes.

Purpose of the Study:

  • To review VEGF-pathway-oriented treatments for iodine-refractory DTC.
  • To discuss the role of VEGF in DTC progression and therapeutic strategies.
  • To explore future prospects of VEGF-targeted therapies in DTC.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of molecular pathways involved in DTC.
  • Evaluation of VEGF-targeted therapeutics.

Main Results:

  • VEGF signaling is a key driver in aggressive DTC.
  • VEGF-targeted therapies show promise in preclinical and clinical settings.
  • Several VEGF-pathway inhibitors are under investigation for DTC.

Conclusions:

  • VEGF-targeted treatments represent a significant advancement for iodine-refractory DTC.
  • Further research is needed to optimize VEGF-pathway-oriented strategies.
  • Future prospects include personalized medicine approaches targeting VEGF in DTC.
Keywords:
Iodine-refractorySorafenibSunitinibSystemic therapyThyroid carcinomaVEGF

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
6
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
9.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
5
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K